{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T08:06:21Z","timestamp":1784102781508,"version":"3.55.0"},"reference-count":30,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomed Rep"],"DOI":"10.3892\/br.2026.2165","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T12:07:17Z","timestamp":1781266037000},"page":"1-15","source":"Crossref","is-referenced-by-count":0,"title":["Semaglutide and major adverse cardiovascular events in patients with and without DM: A systematic review and meta\u2011analysis"],"prefix":"10.3892","volume":"25","author":[{"given":"Yanhua","family":"Li","sequence":"first","affiliation":[{"name":"Emergency department of Dongying People's Hospital, Dongying, Shandong 257092, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunmei","family":"Lv","sequence":"additional","affiliation":[{"name":"Emergency department of Dongying People's Hospital, Dongying, Shandong 257092, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianlian","family":"Cao","sequence":"additional","affiliation":[{"name":"Emergency department of Dongying People's Hospital, Dongying, Shandong 257092, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun","family":"Lihua","sequence":"additional","affiliation":[{"name":"Emergency department of Dongying People's Hospital, Dongying, Shandong 257092, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqu","family":"Ma","sequence":"additional","affiliation":[{"name":"Emergency department of Dongying People's Hospital, Dongying, Shandong 257092, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"key20260715102402_b1-BR-25-2-02165","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: Cardiovascular benefits and mechanisms of action","volume":"20","author":"Ussher","year":"2023","journal-title":"Nat Rev Cardiol"},{"issue":"1293926","key":"key20260715102402_b2-BR-25-2-02165","doi-asserted-by":"publisher","DOI":"10.3389\/fcdhc.2023.1293926","article-title":"The benefits of GLP1 receptors in cardiovascular diseases","volume":"4","author":"Ferhatbegovi\u0107","year":"2023","journal-title":"Front Clin Diabetes Healthc"},{"key":"key20260715102402_b3-BR-25-2-02165","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1093\/cvr\/cvz323","article-title":"Cardiovascular effects of glucagon-like peptide 1 receptor agonists: From mechanistic studies in humans to clinical outcomes","volume":"116","author":"Heuvelman","year":"2020","journal-title":"Cardiovasc Res"},{"key":"key20260715102402_b4-BR-25-2-02165","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1001\/jama.2023.23508","article-title":"Semaglutide improved cardiovascular health in people without diabetes","volume":"330","author":"Harris","year":"2023","journal-title":"JAMA"},{"issue":"q53","key":"key20260715102402_b5-BR-25-2-02165","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.q53","article-title":"Semaglutide reduces the absolute risk of major cardiovascular events by 1.5","volume":"384","author":"Phizackerley","year":"2024","journal-title":"BMJ"},{"key":"key20260715102402_b6-BR-25-2-02165","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1016\/j.jacc.2024.08.022","article-title":"Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT): Outcomes by sex","volume":"84","author":"Verma","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"key20260715102402_b7-BR-25-2-02165","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.2337\/dc24-0764","article-title":"Semaglutide and cardiovascular outcomes by baseline HbA1c and change in HbA1c in people with overweight or obesity but without diabetes in SELECT","volume":"47","author":"Lingvay","year":"2024","journal-title":"Diabetes Care"},{"key":"key20260715102402_b8-BR-25-2-02165","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"key20260715102402_b9-BR-25-2-02165","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"key20260715102402_b10-BR-25-2-02165","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): A double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"key20260715102402_b11-BR-25-2-02165","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"key20260715102402_b12-BR-25-2-02165","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1056\/NEJMc1615712","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"376","author":"Marso","year":"2017","journal-title":"N Engl J Med"},{"key":"key20260715102402_b13-BR-25-2-02165","doi-asserted-by":"publisher","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide","volume":"58","author":"Lau","year":"2015","journal-title":"J Med Chem"},{"key":"key20260715102402_b14-BR-25-2-02165","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"key20260715102402_b15-BR-25-2-02165","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"key20260715102402_b16-BR-25-2-02165","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"key20260715102402_b17-BR-25-2-02165","doi-asserted-by":"publisher","first-page":"765","DOI":"10.2337\/dc20-1473","article-title":"Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11)","volume":"44","author":"Frias","year":"2021","journal-title":"Diabetes Care"},{"issue":"n71","key":"key20260715102402_b18-BR-25-2-02165","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"key20260715102402_b19-BR-25-2-02165","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/s0197-2456(99)00026-4","article-title":"Assessing the quality of randomized trials: Reliability of the Jadad scale","volume":"20","author":"Clark","year":"1999","journal-title":"Control Clin Trials"},{"key":"key20260715102402_b20-BR-25-2-02165","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: The STEP 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"key":"key20260715102402_b21-BR-25-2-02165","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: The STEP 8 randomized clinical trial","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"key":"key20260715102402_b22-BR-25-2-02165","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"key20260715102402_b23-BR-25-2-02165","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"key":"key20260715102402_b24-BR-25-2-02165","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): A randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"key":"key20260715102402_b25-BR-25-2-02165","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"key":"key20260715102402_b26-BR-25-2-02165","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: The STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat Med"},{"key":"key20260715102402_b27-BR-25-2-02165","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.amjcard.2024.04.041","article-title":"Long-term efficacy and safety of once-weekly semaglutide for weight loss in patients without diabetes: A systematic review and meta-analysis of randomized controlled trials","volume":"222","author":"Moiz","year":"2024","journal-title":"Am J Cardiol"},{"key":"key20260715102402_b28-BR-25-2-02165","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41366-024-01646-9","article-title":"Semaglutide effects on safety and cardiovascular outcomes in patients with overweight or obesity: A systematic review and meta-analysis","volume":"49","author":"Cleto","year":"2025","journal-title":"Int J Obes (Lond)"},{"issue":"e245586","key":"key20260715102402_b29-BR-25-2-02165","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2024.5586","article-title":"Lifetime health effects and cost-effectiveness of tirzepatide and semaglutide in US adults","volume":"6","author":"Hwang","year":"2025","journal-title":"JAMA Health Forum"},{"key":"key20260715102402_b30-BR-25-2-02165","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.cjca.2024.09.025","article-title":"Cost-effectiveness of semaglutide in patients with obesity and cardiovascular disease","volume":"41","author":"Rennert-May","year":"2025","journal-title":"Can J Cardiol"}],"container-title":["Biomedical Reports"],"original-title":[],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T07:24:06Z","timestamp":1784100246000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/br.2026.2165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,6,12]]}},"URL":"https:\/\/doi.org\/10.3892\/br.2026.2165","relation":{},"ISSN":["2049-9434","2049-9442"],"issn-type":[{"value":"2049-9434","type":"print"},{"value":"2049-9442","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]}}}